Citrulline Allo. Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children
Recruitment status was: Recruiting
|Study Design:||Time Perspective: Prospective|
|Official Title:||Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children|
- Citrullinemia (weekly) [ Time Frame: weekly ] [ Designated as safety issue: Yes ]
- Gastro-intestinal complications in children following allogeneic bone marrow transplantation [ Time Frame: following allogenic bone marrow transplantation ] [ Designated as safety issue: Yes ]
|Study Start Date:||April 2008|
|Estimated Study Completion Date:||September 2009|
|Estimated Primary Completion Date:||September 2009 (Final data collection date for primary outcome measure)|
30 children included. Dosage of citrullinemia on day -7, day 0 and every week up to 100 days after BMT. Histological examination and extensive infectious screening in case of persistent digestive symptoms (more than 3 days).
Two groups of patients regarding on digestive involvement. Comparison of the values of citrullinemia between these two groups.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00751452
|Clermont-Ferrand, France, 63003|
|Principal Investigator:||Merlin Etienne, Dr||University Hospital, Clermont-Ferrand|